Cambridge Cognition spin-out Monument Therapeutics accesses £1.5m for schizophrenia clinical development Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that Monument Therapeutics Limited (“Monument”) a p.
EARNINGS: Anexo revenue up; Maintel hails confident start to 2024 lse.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lse.co.uk Daily Mail and Mail on Sunday newspapers.